ClinicaliQ Trial Snapshot
- A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting — Recruiting • Cardiology / Cardiovascular • NCT07235462.
- Treatment being tested: Acoramidis, a transthyretin stabiliser designed to prevent misfolding and accumulation of amyloid fibrils in the heart muscle of patients with ATTR-CM.
- Patient eligibility overview: Adults with confirmed transthyretin amyloid cardiomyopathy (ATTR-CM), encompassing both hereditary (ATTRv) and wild-type (ATTRwt) forms, assessed in real-world clinical practice settings across the NHS.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a serious and life-threatening condition where a protein called transthyretin (TTR) misfolds and builds up as amyloid fibrils in the heart muscle. This buildup causes the heart to become stiff, leading to restrictive cardiomyopathy and progressive heart failure. There are two forms of ATTR-CM: a hereditary or 'variant' form (vATTR-CM) caused by a gene mutation, and a 'wild-type' form (wtATTR-CM) which is associated with aging. Because its symptoms can be similar to other heart conditions, ATTR-CM is often diagnosed late. However, recent advances in medical…
Eligibility Snapshot
- : * - Adults (≥18 years at the date of signing the informed consent form (ICF)). * Diagnosis of either wild-type or variant ATTR-CM. * Signed ICF. * Decision to initiate treatment with acoramidis was made as per treating investigator's routine treatment practice before signature of ICF. * Treatment start with acoramidis within 90 days after signing the ICF, with the possibility of starting acoramidis on the same day as signing the ICF.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.